Skip Navigation



Carcinogenesis Advance Access published online on August 25, 2008

Carcinogenesis, doi:10.1093/carcin/bgn200
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
29/11/2139    most recent
bgn200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Yokoyama, T.
Right arrow Articles by Sekido, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yokoyama, T.
Right arrow Articles by Sekido, Y.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation

Toshihiko Yokoyama1, Hirotaka Osada1,2, Hideki Murakami1, Yoshio Tatematsu1, Tetsuo Taniguchi1, Yutaka Kondo1, Yasushi Yatabe3, Yoshinori Hasegawa4, Kaoru Shimokata5, Yoshitsugu Horio6, Toyoaki Hida6 and Yoshitaka Sekido1,*

1 Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan
2 Department of Cellular Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
3 Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan
4 Department of Respiratory Medicine, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
5 College of Life and Health Sciences, Department of Biomedical Sciences, Chubu University, 1200 Matsumotocho, Kasugai, 487-8501, Japan
6 Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan

* Correspondence to: Y. Sekido, Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan. E-mail:ysekido{at}aichi-cc.jp

We previously reported the results of BAC-array-CGH of malignant pleural mesotheliomas (MPMs), including two cases with high-level amplification in the 11q22 locus. In this study, we found that the YAP1 gene encoding a transcriptional co-activator, was localized in this amplified region and overexpressed in both cases, suggesting it as a candidate oncogene in this region. We analyzed the involvement of YAP1 in MPM proliferation, as well as its functional and physical interaction with Merlin encoded by the neurofibromatosis type 2 (NF2) tumor-suppressor gene, which is frequently mutated in MPMs. YAP1-RNAi suppressed growth of a mesothelioma cell line NCI-H290 with NF2 homozygous deletion, probably through cell-cycle arrest and apoptosis induction, while YAP1 transfection promoted the growth of MeT-5A, an immortalized mesothelial cell line. We also found that the introduction of NF2 into NCI-H290 induced phosphorylation at Ser127 of YAP1, which was accompanied by reduction of nuclear localization of YAP1, whereas nuclear localization of a YAP1 S127A-mutant was not affected. Furthermore, results of immunoprecipitation and in vitro pull-down assays indicated a physical interaction between Merlin and YAP1. These results suggest that YAP1 is involved in mesothelial cell growth, and that the transcriptional co-activator activity of YAP1 is functionally inhibited by Merlin through the induction of phosphorylation and cytoplasmic retention of YAP1. This is the first report of negative-regulatory signaling from Merlin to YAP1 in mammalian cells. Future studies of transcriptional targets of YAP1 in MPMs may shed light on the molecular mechanisms of MPM development and lead to new therapeutic strategies.

Key Words: mesothelioma • amplification • YAP1 • merlin/NF2

Received April 9, 2008; revised August 10, 2008; accepted August 20, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Sci SignalHome page
G. Blandino, Y. Shaul, S. Strano, M. Sudol, and M. Yaffe
The Hippo Tumor Suppressor Pathway: A Brainstorming Workshop
Sci. Signal., November 3, 2009; 2(95): mr6 - mr6.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Zhao, J. Kim, X. Ye, Z.-C. Lai, and K.-L. Guan
Both TEAD-Binding and WW Domains Are Required for the Growth Stimulation and Oncogenic Transformation Activity of Yes-Associated Protein
Cancer Res., February 1, 2009; 69(3): 1089 - 1098.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.